5 Questions for an MDMA-assisted Therapy Practitioner

In a Phase II trial of patients who suffered from chronic, treatment-resistant PTSD for an average of 17 years, 56% showed no signs of the condition after one MDMA-assisted therapy session. Following up at the one-year mark, 68% no longer had PTSD.

That’s why a much better fit for Stage 2 is MDMA, as in the right context, this medicine can act similarly to ketamine, in that it creates safety while also tending to “bring up” more from the subterranean “grief well” than ketamine usually can.